Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series

Fig. 2

Radiographic images of enrolled patients. Radiographic images of Case 1(a), Case 2 (b), Case 3 (c), Case 4 (d). a The enhanced lesion was decreased 15 months, and recurrent lesion was observed at the removal site 18 months after the first vaccination. b The enhanced lesion was decreased 12 months, and recurrent lesion was observed at the removal site 17 months after the first vaccination. c The enhanced lesion disappeared 12 months after the first vaccination. d The enhancement lesion disappeared 12 months after the first vaccination

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us